Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$506.34 USD
+2.50 (0.50%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $506.75 +0.41 (0.08%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$506.34 USD
+2.50 (0.50%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $506.75 +0.41 (0.08%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Zacks News
Intuitive Surgical (ISRG) Gains on Strength in Robotics
by Zacks Equity Research
Higher adoption of Intuitive Surgical's (ISRG) robot-based da Vinci system and increasing procedure volumes are key catalysts at the moment.
Myriad Genetics' Prolaris Expands on New Coverage Decisions
by Zacks Equity Research
This increased rate in commercial insurer coverage for Myriad Genetics' (MYGN) Prolaris comes close on the heels of the NCCN guidelines.
McKesson (MCK) Q4 Earnings Miss, International Sales Rise
by Zacks Equity Research
McKesson (MCK) posts strong segmental performance and issues encouraging guidance for fiscal 2019.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Boston Scientific's (BSX) inorganic expansion plan bodes well for operational growth.
Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing
by Zacks Equity Research
Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.
Medtronic (MDT) Q4 Earnings: Can Spine Division Turn Around?
by Zacks Equity Research
Medtronic (MDT) expects to demonstrate positive outcome related to its distribution relationship with Mazor Robotics.
Zimmer Biomet New System Gets FDA Nod, to Boost Spine Wing
by Zacks Equity Research
Zimmer Biomet (ZBH) receives FDA's approval for the new system, which is likely to augment the company's lumbar spacers portfolio.
Cardiovascular Systems Rides on New Products Amid Tight Race
by Zacks Equity Research
Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.
Will Solid Diabetes Arm Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is poised to gain on strength in Diabetes business in Q4 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.
ResMed Releases Positive U.S. & U.K. Study Data on COPD
by Zacks Equity Research
ResMed (RMD) presents the company-sponsored health economic studies, Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV), at the ATS 2018 International Conference.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) gains ground on product launches and international prospects.
Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is poised to gain on continued strength in RTG business in Q4.
Varian Medical (VAR) Merges With Brazil MOH to Fight Cancer
by Zacks Equity Research
Varian Medical (VAR) opts to spread radiotherapy accessibility in Latin America through Brazil MOH, other international ventures of the company hold promise.
Here's Why You Should Steer Clear of Cerner (CERN) for Now
by Zacks Equity Research
Cerner's (CERN) downbeat view for 2018 and soft Q1 results fail to cheer investors.
Here's Why You Should Sell DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
A rapidly changing healthcare environment in the United States, sluggish first quarter, declining margins and foreign exchange headwinds continue to hurt DENTSPLY SIRONA (XRAY).
QIAGEN (QGEN) Banks on Test Menu Expansion, Competition Stiff
by Zacks Equity Research
QIAGEN's (QGEN) top line continues to gain on expanding test menu amid stiff competition and declining HPV sales.
Medtronic Initiates Study on DES for Expanded Use in the US
by Zacks Equity Research
Medtronic (MDT) focuses on boosting CSH segment. Notably, successful results from The Bifurcation Cohort study will help the company to achieve expanded FDA approval for the Resolute Onyx DES.
Intuitive Surgical (ISRG) Up 4.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Illumina Takes Over Edico Genome, Fortifies NGS Platform
by Zacks Equity Research
Illumina (ILMN) proceeds with deals to boost NGS platform.
BioScrip's Core Business Strong Despite Reimbursement Issues
by Zacks Equity Research
BioScrip (BIOS) consistently advances with its multi-faceted CORE plan to perk up the money matters. However, reimbursement cuts pertaining to 21st century Cures Act might hinder growth in 2018.
Mellanox Technologies, MGM Resorts International, BP, Texas Instruments and Intuitive Surgical highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Mellanox Technologies, MGM Resorts International, BP, Texas Instruments and Intuitive Surgical highlighted as Zacks Bull and Bear of the Day
GNC Holdings' Global Prospects Solid, Competition Stiff
by Zacks Equity Research
GNC Holdings (GNC) progresses with deals to boost international presence.
CryoLife (CRY) Stock Gains 9.5% on Impressive Q1 Earnings
by Zacks Equity Research
CryoLife's (CRY) shares gain on growth in all product lines along with strong performance in all geographies in Q1.
TransEnterix (TRXC) Soars: Stock Adds 14.2% in Session
by Zacks Equity Research
TransEnterix (TRXC) saw a big move last session, as its shares jumped more than 14% on the day, amid huge volumes.
Orthofix (OFIX) Stock Declines 13% on '18 Earnings View Cut
by Zacks Equity Research
Despite the bottom line of Orthofix (OFIX) betters estimates, the company's shares drop due to trimmed 2018 earnings outlook.